Long-Term Prognosis of Dilated Cardiomyopathy Revisited An Improvement in Survival Over the Past 20 Years

• Matsumura Yoshihisa

  Department of Medicine and Geriatrics, Kochi Medical School, Kochi University

• Takata Jun

  Department of Medicine and Geriatrics, Kochi Medical School, Kochi University

• Kitaoka Hiroaki

  Department of Medicine and Geriatrics, Kochi Medical School, Kochi University

• Kubo Toru

  Department of Medicine and Geriatrics, Kochi Medical School, Kochi University

• Baba Yuichi

  Department of Medicine and Geriatrics, Kochi Medical School, Kochi University

• Hoshikawa Eri

  Department of Medicine and Geriatrics, Kochi Medical School, Kochi University

• Hamada Tomoyuki

  Department of Medicine and Geriatrics, Kochi Medical School, Kochi University

• Okawa Makoto

  Department of Medicine and Geriatrics, Kochi Medical School, Kochi University

• Hitomi Nobuhiko

  Department of Medicine and Geriatrics, Kochi Medical School, Kochi University

• Sato Kyoko

  Department of Medicine and Geriatrics, Kochi Medical School, Kochi University

• Yamasaki Naohito

  Department of Medicine and Geriatrics, Kochi Medical School, Kochi University

• Yabe Toshikazu

  Department of Medicine and Geriatrics, Kochi Medical School, Kochi University

• Furuno Takashi

  Department of Medicine and Geriatrics, Kochi Medical School, Kochi University

• Nishinaga Masanori

  Department of Medicine and Geriatrics, Kochi Medical School, Kochi University

• Doi Yoshinori

  Department of Medicine and Geriatrics, Kochi Medical School, Kochi University

Bibliographic Information

Other Title

• An Improvement in Survival Over the Past 20 Years

Abstract

Background Because of their favorable prognostic effects, angiotensin converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB) and β blockers have become background therapy in dilated cardiomyopathy (DCM). However, there are few reports concerning the long-term prognosis of Japanese patients with DCM in relation to these treatments. Methods and Results One hundred and fifty patients with DCM were divided into 2 groups: group A (n=46) (diagnosis: 1982-1989) and group B (n=104) (diagnosis: 1990-2002). During follow-up period of 6.9±4.8 years, 62 patients died and 1 patient had a heart transplant. The survival rate at 5 and 10 years was 60.9% and 34.8%, respectively, in group A patients, and 80.9% and 65.3%, respectively, in group B patients (p=0.0079). In group A patients, ACEI/ARB or β blockers were less frequently used (p<0.0001), whereas antiarrhythmics (class Ia or Ib) were more often used (p<0.0001). The patients treated with ACEI/ARB and β blockers showed a better survival rate than those without (p<0.0001). The patients with antiarrhythmics showed a worse survival rate than those without (p<0.0001). Conclusion The prognosis of Japanese patients with DCM has significantly improved over the past 20 years. This improvement may be explained partly through the increased use of ACEI/ARB and β blockers and a declining use of antiarrhythmics. (Circ J 2006; 70: 376 - 383)<br>

Journal

• Circulation Journal

  Circulation Journal 70 (4), 376-383, 2006

  The Japanese Circulation Society

Keywords

• Dilated cardiomyopathy
• Prognosis

Details

• CRID: 1390001205102737408
• NII Article ID: 110004497221
• NII Book ID: AA11591968
• DOI: 10.1253/circj.70.376
• ISSN: 13474820
• ISSN: 13469843
• ISSN: http://id.crossref.org/issn/13469843
• Web Site: http://www.jstage.jst.go.jp/article/circj/70/4/70_4_376/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2007049595
• Text Lang: en
• Data Source:
  • JaLC
  • Crossref
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed